Managing idiopathic short stature: role of somatropin (rDNA origin) for injection

J Paul Frindik1, Stephen F Kemp11University of Arkansas for Medical Sciences and Arkansas Children&rsquo;s Hospital, AR, USAAbstract: Idiopathic short stature (ISS) is a term that describes short stature in children who do not have growth hormone (GH) deficiency and in whom the etiology of t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	J Paul Frindik, Stephen F Kemp
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/235c49d9bd574a9f828f85a8bfcec195
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:235c49d9bd574a9f828f85a8bfcec195
record_format	dspace
spelling	oai:doaj.org-article:235c49d9bd574a9f828f85a8bfcec1952021-12-02T02:02:36ZManaging idiopathic short stature: role of somatropin (rDNA origin) for injection1177-54751177-5491https://doaj.org/article/235c49d9bd574a9f828f85a8bfcec1952010-06-01T00:00:00Zhttp://www.dovepress.com/managing-idiopathic-short-stature-role-of-somatropin-rdna-origin-for-i-a4563https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491J Paul Frindik1, Stephen F Kemp11University of Arkansas for Medical Sciences and Arkansas Children&rsquo;s Hospital, AR, USAAbstract: Idiopathic short stature (ISS) is a term that describes short stature in children who do not have growth hormone (GH) deficiency and in whom the etiology of the short stature is not identified. Between 1985 and 2000, more than 40 studies were published regarding GH therapy for ISS. Only 12 of these had data to adult height, of which only 4 were controlled studies. A subsequent placebo-controlled study that followed subjects to adult height indicated that there was a gain of 3.7&ndash;7.5 cm in height with GH treatment. In 2003, the US Federal Drug Administration (FDA) approved GH for treatment of short stature. Even before FDA approval, patients with ISS made up about 20% of patients in GH databases, which is largely unchanged since FDA approval. There remains some controversy as to whether GH should be used to treat ISS. This controversy centers on the fact that there has been no definitive demonstration that short stature results in a disadvantage or problems with psychological adjustment, and thus, no demonstration that GH therapy results in improvement in quality of life.Keywords: idiopathic short stature, ISS, growth hormone therapy, somatotropin, somatropin, insulin-like growth factor I, IGF-1 J Paul FrindikStephen F KempDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 147-155 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 J Paul Frindik Stephen F Kemp Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
description	J Paul Frindik1, Stephen F Kemp11University of Arkansas for Medical Sciences and Arkansas Children&rsquo;s Hospital, AR, USAAbstract: Idiopathic short stature (ISS) is a term that describes short stature in children who do not have growth hormone (GH) deficiency and in whom the etiology of the short stature is not identified. Between 1985 and 2000, more than 40 studies were published regarding GH therapy for ISS. Only 12 of these had data to adult height, of which only 4 were controlled studies. A subsequent placebo-controlled study that followed subjects to adult height indicated that there was a gain of 3.7&ndash;7.5 cm in height with GH treatment. In 2003, the US Federal Drug Administration (FDA) approved GH for treatment of short stature. Even before FDA approval, patients with ISS made up about 20% of patients in GH databases, which is largely unchanged since FDA approval. There remains some controversy as to whether GH should be used to treat ISS. This controversy centers on the fact that there has been no definitive demonstration that short stature results in a disadvantage or problems with psychological adjustment, and thus, no demonstration that GH therapy results in improvement in quality of life.Keywords: idiopathic short stature, ISS, growth hormone therapy, somatotropin, somatropin, insulin-like growth factor I, IGF-1
format	article
author	J Paul Frindik Stephen F Kemp
author_facet	J Paul Frindik Stephen F Kemp
author_sort	J Paul Frindik
title	Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
title_short	Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
title_full	Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
title_fullStr	Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
title_full_unstemmed	Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
title_sort	managing idiopathic short stature: role of somatropin (rdna origin) for injection
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/235c49d9bd574a9f828f85a8bfcec195
work_keys_str_mv	AT jpaulfrindik managingidiopathicshortstatureroleofsomatropinrdnaoriginforinjection AT stephenfkemp managingidiopathicshortstatureroleofsomatropinrdnaoriginforinjection
_version_	1718402697544073216

Managing idiopathic short stature: role of somatropin (rDNA origin) for injection

Ejemplares similares